IXICO plc Publication of Circular (2054G)

TIDMIXI

RNS Number : 2054G

IXICO plc

18 November 2015

IXICO plc

("IXICO" or the "Company")

Publication of Circular and Notice of General Meeting

18 November 2015: IXICO plc (AIM: IXI), the brain health company, today confirms that further to the announcement made earlier today, a Circular has been published and will be posted to shareholders today in relation to the Proposed Acquisition, Placing, Broker Option, Rule 9 Waiver and Share Restructuring (all of which remain subject to approval by shareholders at a General Meeting to be held on 7 December 2015).

A copy of the Circular will shortly be available on the Company's website at the following URL: http://www.ixico.com/investors/companydocuments.

For further information, please contact:

 
 IXICO plc                          Tel: +44 (0) 20 3763 7499 
 Derek Hill, CEO 
 Susan Lowther, CFO 
 Charles Spicer, VP Corporate 
  Development 
 
 Peel Hunt LLP (Nominated Adviser   Tel: +44 (0) 20 7418 8900 
  and Broker) 
 James Steel 
 Oliver Jackson 
 Sohail Akbar 
 
 FTI Consulting Limited (Investor   Tel: +44 (0) 20 3727 1000 
  Relations) 
 Simon Conway 
 Mo Noonan 
 Matthew Moss

Notes to Editors

About IXICO

IXICO, the brain health company, uses its innovative and proprietary digital platform technologies to help those involved in researching and treating serious diseases to make rapid, informed decisions targeted at improving patient outcomes. IXICO has significant experience working with global pharmaceutical and biotechnology companies supporting clinical studies in the field of neuro-degenerative disorders including dementia, Alzheimer's disease, Huntington's disease and Multiple Sclerosis.

More information is available on www.ixico.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

CIRPKFDNPBDDNDD

(END) Dow Jones Newswires

November 18, 2015 10:45 ET (15:45 GMT)

Phytopharm (LSE:PYM)
過去株価チャート
から 11 2024 まで 12 2024